Analysts Change Price Targets on Shares of These Healthcare Companies

Wall St. Watchdog reveals information about companies for which stock analysts reiterated ratings in the Healthcare sector for the week ending November 11th, 2011.

  • Cardiome Pharma (NASDAQ:CRME): RBC Capital Mkts reiterated its rating of Outperform for this company and changed its price target from $9 to $6 on Nov 7th. The shares recently traded at $2.42, down $0.32, or 11.68% since the analyst’s rating. About the company: Cardiome Pharma Corp. is a product-focused cardiovascular drug development company with clinical drug programs. The Company’s programs focus on atrial arrhythmia and congestive heart failure. Get the most recent company news and stock data here >>
  • Brookdale Senior Living (NYSE:BKD): RBC Capital Mkts reiterated its rating of Outperform for this company and changed its price target from $28 to $26 on Nov 7th. The shares recently traded at $15.52, down $0.83, or 5.08% since the analyst’s rating. About the company: Brookdale Senior Living Inc. operates senior living facilities in the United States. The Company offers its residents access to a full continuum of services across all sectors of the senior living industry. Brookdale Senior operates independent living facilities, assisted living facilities, continuing care retirement communities, and a skilled nursing facility. Get the most recent company news and stock data here >>
  • Inhibitex (NASDAQ:INHX): Canaccord Genuity reiterated its rating of Buy for this company and changed its price target from $7 to $15. Brean Murray reiterated its rating of Buy for this company and changed its price target from $6 to $12 on Nov 7th. The shares recently traded at $9.11, down $0.61, or 6.28% since the analyst’s rating. About the company: Inhibitex Inc. is a biopharmaceutical company that discovers, develops, and commercializes novel antibody-based products. The Company develops products for the prevention and treatment of serious bacterial and fungal infections in the hospital setting. Get the most recent company news and stock data here >>
  • Medicis (NYSE:MRX): UBS reiterated its rating of Neutral for this company and changed its price target from $37 to $39 on Nov 9th. The shares recently traded at $35.55, down $0.71, or 1.96% since the analyst’s rating. About the company: Medicis Pharmaceutical Corporation provides pharmaceuticals focusing on the treatment of dermatological, pediatric, and podiatric conditions, as well as aesthetics medicine. The Company has branded prescription products in therapeutic categories such as acne, asthma, eczema, fungal infections, hyperpigmentation, photoaging, psoriasis, and rosacea. Get the most recent company news and stock data here >>
  • Warner Chilcott (NASDAQ:WCRX): UBS reiterated its rating of Buy for this company and changed its price target from $28 to $24 on Nov 10th. The shares recently traded at $16.93, down $0.1, or 0.59% since the analyst’s rating. About the company: Warner Chilcott PLC is a pharmaceutical company. The Company is focused on marketing, selling, developing and manufacturing branded prescription pharmaceutical products in women’s healthcare and dermatology in the United States. Get the most recent company news and stock data here >>
  • MAKO Surgical (NASDAQ:MAKO): Canaccord Genuity reiterated its rating of Hold for this company and changed its price target from $24.5 to $30 on Nov 10th. The shares recently traded at $33.98, up $1.17, or 3.57% since the analyst’s rating. About the company: MAKO Surgical Corp. is a medical device company. The Company offers robotic-ARM solutions and implants for minimally invasive orthopedic knee procedures. Get the most recent company news and stock data here >>
  • Medivation (NASDAQ:MDVN): Rodman & Renshaw reiterated its rating of Mkt Underperform for this company and changed its price target from $19 to $29 on Nov 10th. The shares recently traded at $41.00, up $0.99, or 2.47% since the analyst’s rating. About the company: Medivation Inc. acquires, develops, and sells or partners biomedical technologies in the early development stage of the research and development process. Get the most recent company news and stock data here >>
  • Salix Pharma (NASDAQ:SLXP): Brean Murray reiterated its rating of Buy for this company and changed its price target from $50 to $53 on Nov 10th. The shares recently traded at $33.85, down $2.67, or 7.31% since the analyst’s rating. About the company: Salix Pharmaceuticals, Ltd. develops and markets prescription pharmaceutical products for the treatment of gastrointestinal diseases. The Company markets its products to gastroenterologists in the U.S. through its own specialty sales force. Get the most recent company news and stock data here >>

(Note: Selected financial data are sourced from Briefing.com via the Wall St. Journal. All data are assumed to be accurate.)

Advantage: Check out our interactive stock charts, fundamentals, Twitter stream, and more >>

Improve Your 2011 Financial Health: Join the winning team of stock pickers with Wall St. Cheat Sheet’s acclaimed premium newsletter>>